查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1978941

切片检查钳市场：2026-2032年全球市场按产品类型、应用、最终用户和分销管道分類的预测

Biopsy Forceps Market by Product Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，切片检查钳市场价值将达到 2.3478 亿美元，到 2026 年将成长至 2.4936 亿美元，到 2032 年将达到 3.5778 亿美元，年复合成长率为 6.20%。

主要市场统计数据
基准年 2025 2.3478亿美元
预计年份：2026年 2.4936亿美元
预测年份 2032 3.5778亿美元
复合年增长率 (%) 6.20%

对切片检查钳进行临床和操作概述，反映了影响其应用的程序要求、设备设计进步和消毒优先事项的交汇点。

切片检查钳是诊断性内视镜检查中的基本器械，可用于肺部、胃肠道、妇科和泌尿系统手术中的组织取样。近年来，临床趋势表明，切片检查器械作为精准辅助器具的作用日益增强，对诊断准确性、手术时间和后续治疗方案的製定都具有显着影响。随着临床医生优先考虑微创治疗方法，对兼具操作性、触觉回馈和检体品质一致性的器械的需求也日益增长。这一趋势正在影响产品研发週期、监管机构的关注点以及医院的采购标准。

临床实践的进步、消毒要求的提高以及製造技术的创新如何从根本上改变切片检查钳的开发和采购？

切片检查钳市场正经历着变革性的转变，其根源在于临床实践的演变、供应链的调整以及产品创新。其中一个显着的变化是，在某些临床环境中，为了降低交叉感染的风险并简化再处理流程，一次性器械的使用正在兴起。这种转变催生了性能更优的一次性器械设计，这些器械在满足无菌性和物流需求的同时，也能提供与可重复使用器械相媲美的性能。同时，可重复使用器械也在不断发展，采用更先进的高压釜材料，并相容于化学灭菌，从而在优先考虑生命週期经济性和环境因素的场合保持其效用。

本文探讨了 2025 年关税改革对切片检查钳相关人员的筹资策略、采购惯例和製造地决策的影响。

美国于2025年宣布的关税措施的累积影响，正使切片检查钳采购和全球筹资策略日益复杂。关税调整迫使许多製造商和医疗系统负责人重新评估其供应商所在地，特别是从高关税地区进口的零件和成品。为此，一些原始设备製造商（OEM）正在加快近岸外包和本土化生产，以维持价格稳定、缩短前置作业时间并保护供应链免受贸易政策波动的影响。这些变化的影响远不止于贸易问题，还波及製造品质系统、监管备案和供应商认证计画。

详细的細項分析揭示了产品灭菌途径、治疗应用、医疗环境和分销网络如何决定竞争差异化。

基于细分市场的洞察揭示了产品特性、临床应用、使用环境和通路如何共同影响切片检查钳市场的策略定位。根据产品类型，市场被分为「可重复使用」和「一次性使用」两类。可重复使用产品进一步细分为「高压釜」和「化学灭菌」。一次性产品则进一步细分为非无菌产品和无菌产品。这些区分至关重要，因为灭菌方法、再处理能力和使用后处理都会影响采购标准以及与临床工作流程的适用性。在拥有成熟灭菌能力的大型医疗机构中，高压釜的可重复使用器械往往更受欢迎；而在再处理基础设施有限的医疗机构中，化学灭菌的可重复使用器械和一次性无菌产品可能更为合适。

区域比较观点揭示了采购优先事项、法规结构和製造能力如何影响全球医疗保健市场对切片检查钳的采用。

区域趋势对切片检查钳的临床应用、采购行为和监管路径有显着影响，美洲、欧洲、中东和非洲以及亚太地区存在不同的驱动因素。在美洲，对病人安全、感染控制和大量采购的重视促使人们考虑在某些手术类型中使用一次性器械。同时，大规模综合医疗网路要求器械的一致性、供应商的可靠性以及可追溯的再处理流程。法律规范往往较为严格，而报销机制也会影响医院层级的器械采购决策和竞标结果。

竞争策略洞察，揭示产品创新、监管应对力和通路伙伴关係如何决定长期差异化和客户维繫。

切片检查钳市场的竞争格局取决于差异化的产品系列、对监管法规的灵活应对以及通路管理。主要企业正致力于提升生产扩充性、推动先进材料科学发展并改进产品设计，以确保组织采集的一致性，同时满足灭菌和再处理标准。与内视镜製造商和临床中心建立策略伙伴关係，能够根据实际操作回馈不断迭代改进产品。同时，一些企业优先发展一次性（可抛弃式）平台，以解决感染控制问题并简化门诊手术流程。

为製造商和采购团队提供可操作的策略重点，以提高产品效能、供应弹性和在临床环境中的商业性差异化。

产业领导企业应采取多管齐下的策略，将产品设计、供应链韧性和以客户为中心的服务结合，以赢得临床机构选型和采购部门的信任。优先开发能够最大限度减少消毒部门额外工作量并保持组织品质一致性的镊子，并确保设计选择与目标终端使用者最常用的消毒方法相符。同时，在具有明显感染控制和工作流程优势的场所扩大一次性产品的供应，并在具有生命週期成本效益的高流量机构中保留可重复使用产品。

说明了一种透明的调查方法，该方法利用相关人员访谈、二次检验和检验通讯协定来得出策略见解，而无需进行定量估计。

本分析所依据的研究透过结合与相关人员的初步定性研究和使用二手资讯的严格三角检验，确保了平衡且基于证据的观点。初步资讯包括呼吸内科、消化内科、妇科和泌尿系统医生的结构化访谈，以及与消毒部门经理、采购负责人和医疗设备工程师的对话。这些对话提供了流程需求、再处理限制和采购决策标准的详细见解。二手资讯包括监管申报文件、医疗设备使用说明书、临床操作指南和公开的供应商新闻稿，这些资讯用于检验从初步研究中得出的主题。

一项权威的综合分析，将医疗设备性能、灭菌工作流程和筹资策略相结合，重点强调了支持在临床环境中可持续部署的实际要求。

总之，切片检查钳仍然是兼顾诊断准确性和操作便利性的关键器械类别。随着临床重点、消毒基础设施和采购框架的不断发展，可重复使用和一次性解决方案之间的平衡仍将是所有医疗机构需要考虑的重要因素。除了材料和人体工学的进步外，人们对感染预防和供应链韧性的日益关注也为能够提供经临床验证且生命週期成本可预测的产品的製造商创造了新的机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：切片检查钳市场：依产品类型划分

  • 可重复使用的
    • 高压釜
    • 化学灭菌
  • 一次性的
    • 非无菌
    • 已灭菌

第九章：切片检查钳市场：按应用领域划分

  • 支气管镜检查
    • 传统的
    • 支气管内超音波
  • 胃肠内视镜检查
    • 大肠镜检查
    • 食道、胃和十二指肠内视镜检查
  • 妇科
  • 泌尿系统

第十章：切片检查钳市场：按最终用户划分

  • 门诊手术中心
  • 诊所
  • 医院

第十一章：切片检查钳市场：按分销管道划分

  • 批发商
  • 医院采购
  • 线上零售

第十二章：切片检查钳市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：切片检查钳市场：按类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：切片检查钳市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国切片检查钳市场

第十六章：中国切片检查钳市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ACE Medical Devices Pvt. Ltd.
  • Anrei medical（hz）co.,Ltd.
  • Argon Medical Devices
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • CONMED Corporation
  • Cook Group Incorporated
  • FUJIFILM Corporation
  • Integer Holdings Corporation
  • Integra LifeSciences Corporation
  • KARL STORZ SE & Co. KG
  • MedGyn Products, Inc.
  • Medi-Globe GmbH
  • Medline Industries, Inc.
  • Medorah Meditek Pvt. Ltd.
  • Medtronic PLC
  • MICRO-TECH（Nanjing）Co., Ltd,
  • Olympus Corporation
  • Omnimed Ltd.
  • PENTAX Medical by Hoya Corporation
  • Scanlan International, Inc.
  • Sklar Surgical Instruments
  • STERIS Corporation
  • Wilson Instruments（SHA）Co., Ltd.
Product Code: MRR-521BAA36EA7F

The Biopsy Forceps Market was valued at USD 234.78 million in 2025 and is projected to grow to USD 249.36 million in 2026, with a CAGR of 6.20%, reaching USD 357.78 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 234.78 million
Estimated Year [2026] USD 249.36 million
Forecast Year [2032] USD 357.78 million
CAGR (%) 6.20%

A concise clinical and operational overview of biopsy forceps reflecting the intersection of procedural demands, device design evolution, and sterilization priorities influencing adoption

Biopsy forceps are fundamental instruments within diagnostic endoscopy, enabling tissue sampling across pulmonary, gastrointestinal, gynecological, and urological procedures. Recent clinical trends have elevated the role of biopsy tools as precision accessories that materially influence diagnostic yield, procedure time, and downstream therapeutic decisions. As clinicians prioritize minimally invasive pathways, the demand for instruments that balance maneuverability, tactile feedback, and consistent sample quality has intensified. This dynamic is shaping product development cycles, regulatory attention, and hospital procurement criteria in parallel.

Technological refinement has progressed along multiple vectors: materials science focused on corrosion resistance and tip sharpness; ergonomic handle designs to reduce clinician fatigue; and manufacturing tolerances that ensure reproducible bite size within narrow anatomical corridors. Concurrently, infection prevention imperatives and sterilization workflows are driving divergent adoption patterns between reusable and single-use products. These operational and clinical drivers intersect with shifting procurement strategies, where value assessments increasingly weigh total cost of ownership, reprocessing logistics, and risk mitigation alongside unit price. The investment case for a biopsy forceps strategy therefore requires synthesis of clinical utility, lifecycle economics, and supply reliability to inform purchasing and product development decisions.

How clinical practice evolution, sterilization imperatives, and manufacturing innovation are driving a fundamental reshaping of biopsy forceps development and procurement

The landscape for biopsy forceps is undergoing transformative shifts rooted in clinical practice changes, supply chain adaptation, and product innovation. One prominent change is the move toward single-use instruments in select clinical settings to reduce cross-contamination risk and simplify reprocessing workflows. This shift is accompanied by enhanced single-use designs that approach the performance of reusable alternatives while addressing sterility and logistics concerns. At the same time, reusable instruments continue to evolve with improved autoclavable materials and chemical sterilization compatibility, ensuring they remain viable where lifecycle economics and environmental considerations are prioritized.

Procedural advancements such as increased uptake of endobronchial ultrasound and refined gastrointestinal endoscopic techniques have raised expectations for forceps precision and access. Device makers are responding with optimized tip profiles, enhanced shaft flexibility, and compatibility with a broader array of endoscope channels. Beyond pure mechanical improvements, integration of digital process controls and traceability features for reprocessed instruments is becoming more common, enabling healthcare facilities to better manage compliance and inventory. The result is a market that rewards manufacturers who can deliver clinical performance, streamlined sterilization pathways, and resilient supply solutions, while payers and procurement teams increasingly evaluate product value through a broader operational lens.

An examination of how 2025 tariff reforms have reshaped sourcing strategies, procurement practices, and manufacturing footprint decisions for biopsy forceps stakeholders

The cumulative impact of United States tariff actions announced for 2025 has introduced measurable complexity into biopsy forceps procurement and global sourcing strategies. Tariff adjustments have prompted many manufacturers and health system buyers to re-evaluate supplier footprints, particularly for components and finished devices imported from regions subject to elevated duties. In response, some original equipment manufacturers have accelerated nearshoring and onshoring initiatives to preserve price stability, shorten lead times, and insulate supply lines from trade policy volatility. These shifts are not purely transactional; they carry implications for manufacturing quality systems, regulatory filings, and supplier qualification timelines.

Procurement teams have reacted by revising contract terms, increasing emphasis on total landed cost analysis, and seeking longer-term supply commitments to mitigate future tariff exposures. For distributors and hospital procurement departments, tariff-driven cost pressure has reinforced the importance of diversified supplier panels and strategic stockholding to smooth operational continuity. Additionally, tariff dynamics have stimulated discussions around product portfolio rationalization, where less differentiated items may be consolidated to reduce SKU complexity and import dependencies. Across the value chain, compliance functions have heightened focus on classification, country-of-origin documentation, and tariff engineering opportunities that legally optimize duty treatment without compromising safety or regulatory compliance. The overarching effect is a more deliberate, risk-aware sourcing posture that integrates trade policy considerations into clinical supply planning and product lifecycle decisions.

Deep segmentation analysis revealing how product sterilization pathways, procedural applications, care settings, and distribution networks determine competitive differentiation

Segmentation-driven insight reveals how product characteristics, clinical applications, user settings, and distribution pathways jointly influence strategic positioning within the biopsy forceps arena. Based on Product Type, market is studied across Reusable and Single Use. The Reusable is further studied across Autoclavable and Chemical Sterilization. The Single Use is further studied across Non Sterile and Sterile. These distinctions matter because sterilization modality, reprocessing throughput, and end-of-life handling all feed into purchasing criteria and clinical workflow compatibility. Autoclavable reusable instruments are often favored in high-volume centers with mature sterile processing capacity, whereas chemically sterilized reusables or single-use sterile items may better serve facilities with constrained reprocessing infrastructure.

Based on Application, market is studied across Bronchoscopy, Gastrointestinal Endoscopy, Gynecology, and Urology. The Bronchoscopy is further studied across Conventional and Endobronchial Ultrasound. The Gastrointestinal Endoscopy is further studied across Colonoscopy and Esophagogastroduodenoscopy. Application-specific requirements dictate instrument dimensions, bite geometry, and shaft flexibility. For example, endobronchial ultrasound probes require forceps that maintain performance within narrow working channels while delivering adequate tissue for molecular diagnostics. In gastrointestinal procedures, the need for reliable retrieval during colonoscopy or esophagogastroduodenoscopy drives different design trade-offs between grasp strength and maneuverability.

Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, and Hospitals. Each setting imposes unique operational constraints: ambulatory centers prioritize rapid turnover and simplified reprocessing, clinics may seek cost-effective single-use solutions for lower-volume procedures, and hospitals demand a balance of durability and broad procedural compatibility. Based on Distribution Channel, market is studied across Distributors, Hospital Procurement, and Online Retail. Distribution choice affects lead times, aftermarket support, training offerings, and pricing transparency. The interplay of these segmentation dimensions shapes how manufacturers prioritize R&D investment, channel partnerships, and customer support models to match clinical and operational needs.

A comparative regional perspective clarifying how procurement priorities, regulatory frameworks, and manufacturing capacity shape biopsy forceps adoption across global healthcare markets

Regional dynamics exert strong influence on clinical adoption, procurement behavior, and regulatory pathways for biopsy forceps, with distinct drivers observed in the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, emphasis on patient safety, infection control, and bundled procurement has supported exploration of single-use alternatives in specific procedure types, while large integrated delivery networks demand consistency, supplier reliability, and traceable reprocessing practices. Regulatory oversight tends to be rigorous, and reimbursement structures shape hospital-level adoption decisions and tender outcomes.

In Europe, Middle East & Africa, heterogeneous healthcare systems create a patchwork of adoption rates and procurement preferences. Western European markets often lead in innovation uptake and sustainability conversations, applying lifecycle cost assessments and environmental impact considerations to purchasing decisions. By contrast, other countries in the region may prioritize cost containment and supply chain availability, which can favor robust reusable portfolios. Regulatory harmonization efforts in some jurisdictions influence cross-border sourcing and clinical acceptance.

The Asia-Pacific region is characterized by rapid procedural volume growth, expanding access to endoscopic services, and increasing domestic manufacturing capability. Local production capacity is strengthening, driven by investment in precision manufacturing and competitive positioning for both regional and export markets. Across all regions, clinical education, distributor relationships, and regulatory alignment remain critical to translating product innovation into sustained utilization, and successful market entry strategies must be tailored to each regional ecosystem's procurement norms and clinical priorities.

Insights into competitive strategies showing how product innovation, regulatory readiness, and channel partnerships determine long-term differentiation and customer retention

Competitive dynamics among companies in the biopsy forceps space are defined by differentiated product portfolios, regulatory agility, and channel management. Leading firms are investing in manufacturing scalability, enhanced material sciences, and design refinements that deliver consistent tissue acquisition while meeting sterilization and reprocessing standards. Strategic partnerships with endoscope manufacturers and clinical centers are enabling iterative product improvements guided by real-world procedural feedback. In parallel, some players prioritize single-use platforms to address infection control concerns and simplify logistics for ambulatory environments.

Mergers, acquisitions, and distribution agreements continue to be mechanisms for accelerating market access and closing capability gaps, particularly in regions where local regulatory approvals and established distribution networks are critical. Companies that combine robust regulatory affairs capabilities with localized quality systems can shorten time-to-market for new SKUs. Aftermarket services such as clinician training, reprocessing support, and inventory management are increasingly material to competitive positioning, as buyers reward vendors who reduce operational friction. Manufacturers that focus on demonstrable clinical outcomes, rigorous validation studies, and responsive post-sale support are more likely to secure long-term procurement relationships in an environment where clinical performance and logistical reliability carry significant weight.

Actionable strategic priorities for manufacturers and procurement teams to enhance product performance, supply resilience, and commercial differentiation in clinical settings

Industry leaders should adopt a multi-pronged strategy that aligns product design, supply resilience, and customer-centric services to capture clinical preference and procurement trust. Prioritize development of forceps that deliver consistent tissue quality while minimizing additional workflow burden for sterile processing departments, and ensure that design choices reflect the sterilization modalities most prevalent among target end users. Simultaneously, expand single-use offerings where they provide clear infection prevention or workflow advantages, but maintain reusable options for high-volume centers that benefit from lifecycle economics.

Strengthen supply chain resilience by diversifying suppliers, qualifying alternative manufacturing sites, and considering nearshore production to mitigate tariff and logistics risks. Enhance commercial proposals with transparent total landed cost analyses and evidence packages that link device performance to procedural efficiency or diagnostic yield. Invest in clinician education programs and post-sale support to accelerate adoption and reduce procedural variability. Finally, adopt sustainability practices that address end-of-life handling and packaging optimization, recognizing that environmental considerations increasingly influence purchasing decisions across hospitals and health systems. A disciplined execution of these actions will help organizations balance short-term operational needs with long-term strategic positioning.

A transparent methodological exposition describing stakeholder interviews, secondary validation, and triangulation protocols used to derive strategic insights without quantitative estimations

The research underpinning this analysis combines primary qualitative engagement with stakeholders and rigorous secondary source triangulation to ensure a balanced, evidence-based perspective. Primary inputs included structured interviews with clinicians across pulmonology, gastroenterology, gynecology, and urology, in addition to dialogues with sterile processing managers, procurement professionals, and device engineers. These conversations provided granular insights into procedural needs, reprocessing constraints, and procurement decision criteria. Secondary inputs comprised regulatory filings, device instruction for use documentation, clinical procedure guides, and publicly available supplier announcements, which were used to validate themes emerging from primary research.

Data integrity was sustained through cross-verification across independent sources, coding of qualitative responses to identify recurring patterns, and assessment of regulatory and clinical documentation for consistency. Limitations are acknowledged: the research emphasized qualitative drivers and strategic dynamics rather than providing numerical market estimates; variations in regional clinical practice and procurement policies may generate different local outcomes. Ethical protocols were followed in all primary engagements, with interviewees participating on a non-attributable basis unless explicit permission was granted. The methodology is designed to be transparent and reproducible, offering a defensible foundation for the strategic conclusions and recommendations presented.

A decisive synthesis highlighting the practical imperatives for aligning device performance, sterilization workflows, and procurement strategy to support durable clinical adoption

In conclusion, biopsy forceps remain a pivotal class of instruments at the intersection of diagnostic precision and operational practicality. The balance between reusable and single-use solutions will continue to be negotiated across care settings as clinical priorities, sterilization infrastructure, and procurement frameworks evolve. Technology refinement in materials and ergonomics, coupled with heightened attention to infection prevention and supply resilience, creates opportunities for manufacturers that can deliver validated clinical performance alongside predictable lifecycle economics.

Successful market strategies will be those that integrate clinician-centered design, rigorous regulatory readiness, and supply chain flexibility to adapt to trade policy shifts and regional procurement norms. Providers and procurement teams must weigh clinical benefits against operational impacts and choose solutions that support consistent diagnostic outcomes while minimizing procedural and reprocessing burdens. The imperative is clear: align product development and commercial execution with the practical realities of clinical workflows and procurement constraints to secure sustained adoption and improve patient care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopsy Forceps Market, by Product Type

  • 8.1. Reusable
    • 8.1.1. Autoclavable
    • 8.1.2. Chemical Sterilization
  • 8.2. Single Use
    • 8.2.1. Non Sterile
    • 8.2.2. Sterile

9. Biopsy Forceps Market, by Application

  • 9.1. Bronchoscopy
    • 9.1.1. Conventional
    • 9.1.2. Endobronchial Ultrasound
  • 9.2. Gastrointestinal Endoscopy
    • 9.2.1. Colonoscopy
    • 9.2.2. Esophagogastroduodenoscopy
  • 9.3. Gynecology
  • 9.4. Urology

10. Biopsy Forceps Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Clinics
  • 10.3. Hospitals

11. Biopsy Forceps Market, by Distribution Channel

  • 11.1. Distributors
  • 11.2. Hospital Procurement
  • 11.3. Online Retail

12. Biopsy Forceps Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Biopsy Forceps Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Biopsy Forceps Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Biopsy Forceps Market

16. China Biopsy Forceps Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. ACE Medical Devices Pvt. Ltd.
  • 17.6. Anrei medical (hz)co.,Ltd.
  • 17.7. Argon Medical Devices
  • 17.8. Becton, Dickinson and Company
  • 17.9. Boston Scientific Corporation
  • 17.10. Cardinal Health, Inc.
  • 17.11. CONMED Corporation
  • 17.12. Cook Group Incorporated
  • 17.13. FUJIFILM Corporation
  • 17.14. Integer Holdings Corporation
  • 17.15. Integra LifeSciences Corporation
  • 17.16. KARL STORZ SE & Co. KG
  • 17.17. MedGyn Products, Inc.
  • 17.18. Medi-Globe GmbH
  • 17.19. Medline Industries, Inc.
  • 17.20. Medorah Meditek Pvt. Ltd.
  • 17.21. Medtronic PLC
  • 17.22. MICRO-TECH (Nanjing) Co., Ltd,
  • 17.23. Olympus Corporation
  • 17.24. Omnimed Ltd.
  • 17.25. PENTAX Medical by Hoya Corporation
  • 17.26. Scanlan International, Inc.
  • 17.27. Sklar Surgical Instruments
  • 17.28. STERIS Corporation
  • 17.29. Wilson Instruments (SHA) Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPSY FORCEPS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOPSY FORCEPS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY AUTOCLAVABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY AUTOCLAVABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY AUTOCLAVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CHEMICAL STERILIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CHEMICAL STERILIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CHEMICAL STERILIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY NON STERILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY NON STERILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY NON STERILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY STERILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY STERILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY STERILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ENDOBRONCHIAL ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ENDOBRONCHIAL ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ENDOBRONCHIAL ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY COLONOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY COLONOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ESOPHAGOGASTRODUODENOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ESOPHAGOGASTRODUODENOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ESOPHAGOGASTRODUODENOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GYNECOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GYNECOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GYNECOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY UROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY UROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY UROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY HOSPITAL PROCUREMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY HOSPITAL PROCUREMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY HOSPITAL PROCUREMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GCC BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. GCC BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. G7 BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. G7 BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. NATO BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 192. NATO BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 195. NATO BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. NATO BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL BIOPSY FORCEPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA BIOPSY FORCEPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA BIOPSY FORCEPS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA BIOPSY FORCEPS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA BIOPSY FORCEPS MARKET SIZE, BY SINGLE USE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA BIOPSY FORCEPS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA BIOPSY FORCEPS MARKET SIZE, BY BRONCHOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA BIOPSY FORCEPS MARKET SIZE, BY GASTROINTESTINAL ENDOSCOPY, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA BIOPSY FORCEPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA BIOPSY FORCEPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)